Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

(2021) R. Palich et al.   ANNALS OF ONCOLOGY

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

(2021) Yair Herishanu et al.   BLOOD

Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose

(2021) Evangelos Terpos et al.   BLOOD

Care without a compass: including patients with cancer in COVID-19 studies

(2021) Christopher R. Friese et al.   CANCER CELL

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

(2021) Sarah Bird et al.   Lancet Haematology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

(2021) P. Grivas et al.   ANNALS OF ONCOLOGY

Seroconversion rates following COVID-19 vaccination among patients with cancer

(2021) Astha Thakkar et al.   CANCER CELL

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

(2021) Amir Massarweh et al.   JAMA Oncology

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

(2020) Nicole M Kuderer et al.   LANCET

COVID-19 and Cancer: Current Challenges and Perspectives

(2020) Ziad Bakouny et al.   CANCER CELL

SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19

(2020) Lars F. Westblade et al.   CANCER CELL

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study

(2020) Andrew L. Schmidt et al.   CANCER CELL

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection

(2020) QuanQiu Wang et al.   JAMA Oncology

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples

(2020) Livia Mazzini et al.   JOURNAL OF IMMUNOLOGICAL METHODS